Teresa Jenkins-Mccord
Allergy & Immunology · Albuquerque, NMNPI 1538160379
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 36.0% of the total. 2025 is the largest year on record at $2,532, 2.5 times the $1,004 reported in 2021.
Across 245 payments — averaging $39.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$726
- Pharming Healthcare, Inc.$518
- Blueprint Medicines Corporation$445
- plus $2K from 18 others
What the payments were for
- Food & beverage$9,42197%
- Education$2993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $3,499 |
| GSK | 34 | $1,200 |
| Sanofi | 21 | $1,117 |
| Regeneron Healthcare Solutions, Inc. | 19 | $726 |
| Pharming Healthcare, Inc. | 8 | $518 |
| Blueprint Medicines Corporation | 9 | $445 |
| Incyte Corporation | 12 | $381 |
| Genentech USA, Inc. | 9 | $299 |
| Grifols USA, LLC | 7 | $224 |
| Amgen | 9 | $209 |
| Viatris Specialty LLC | 4 | $194 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $180 |
| Biocryst US Sales Co., LLC | 7 | $143 |
| Mylan Specialty L.p. | 3 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| Novartis | 3 | $84 |
| Sanofi-aventis U.S. LLC | 1 | $77 |
| CSL Behring | 2 | $64 |
| Cycle Pharmaceuticals Inc | 2 | $44 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| LEO Pharma Inc. | 1 | $23 |
| Pfizer | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Bio Products Laboratory USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 28 | $97,595 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $75,461 |
| TezspireTezepelumab-Ekko | 14 | $62,573 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $25,136 |
| Spiriva RespimatTiotropium Bromide | 21 | $19,145 |
| SymbicortBudesonide/Formoterol Fumarate | 53 | $18,033 |
| DuleraMometasone/Formoterol | 27 | $16,880 |
| AlvescoCiclesonide | 27 | $12,417 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,347 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,175 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $8,031 |
| Serevent DiskusSalmeterol Xinafoate | 17 | $7,812 |
| Fluticasone Propionate HfaFluticasone Propionate | 29 | $7,769 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $6,775 |
| Arnuity ElliptaFluticasone Furoate | 25 | $6,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $3,499 | $80,60667 claims |
| CSL BehringHizentra | $64 | $75,46118 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,200 | $40,55163 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $44 | $5,82917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Albuquerque
- Amanda Grippen GoddardAlbuquerque$14K
- Jack GhablyAlbuquerque$14K
- Shanze WangAlbuquerque$12K
- Osman DokmeciAlbuquerque$12K
- Steven TolberAlbuquerque$3K
- Pamela DaffernAlbuquerque$752
- Mark SchuylerAlbuquerque$391
- Katherine Abernathy-CarverAlbuquerque$195
- Valerie TauschAlbuquerque$48
- Michael RuppLas Cruces$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.